Treatment of acute heart failure syndrome – review

1. Nieminen, M. S., Boehm, M., Cowie, M. R. et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur. Heart J., 2005, 26, p. 383–416.

2. American Heart Association Heart Disease and Stroke Statistics – 2004 Update. Dallas, TX : American Heart Association, 2003.

3. Stevenson, R.,Ranjadayalan, K., Wilkinson, P. et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. Br. Med. J., 1993, 307, p. 349–353.

4. Roguin, A., Behar, D., Ben Ami, H. et al. Long-term prognosis of acute pulmonary oedema – an ominous outcome. Eur. J. Heart Fail., 2000, 2, p. 137–144.

5. Krumholz, H. M., Parent, E. M., Tu, N. et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch. Intern. Med., 1997, 157, p. 99–104.

6. Špinar, J., Janský, P., Kettner, J. et al. Doporučení pro diagnostiku a léčbu akutního srdečního selhání. CorVasa, 2006, 48, p. K3–31.

7. Chen, C. H., Nakayama, M., Nevo, E. et al. Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J. Am. Coll. Cardiol., 1998, 32, p. 1221–1227.

8. Cotter, G., Metzkor, E., Kaluski, E. et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet, 1998, 351, 9100, p. 389–393.

9. Narula, J., Haider, N., Virmani, R. et al. Apoptosis in myocytes in end-stage heart failure. N. Engl. J. Med., 1996, 335, p. 1182–1189.

10. Thackray, S., Easthaugh, J., Freemantle, N. et al. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure – a meta-regression analysis. Eur. J. Heart Fail., 2002, 4, p. 515–529.

11. Lowes, B. D., Tsvetkova, T., Eichhorn, E. J. et al. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int. J. Cardiol., 2001, 81, p. 141–149.

12. Felker, G. M., Benza, R. L., Chandler, A. B. et al. Heart failure etiology and response to milrinone in decompensated heart failure. Results from the OPTIME-CHF Study. JACC, 2003, 41, p. 997–1003.

13. Kivikko, M., Lehtonen, L., Colucci, W. S. Sustained hemodynamic effects of intravenous levosimendan. Circulation, 2003, 107, p. 81–86.

14. Innes, C. A., Wagstaff, A. J. Levosimendan: A review of its use in the management of acute decompensated heart failure. Drugs, 2003, 63, p. 2651–2671.

15. Kivikko, M., Antila, S., Eha, J. et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24 h continuous infusion in patients with severe heart failure. Int. J. Clin. Pharmacol. Ther., 2002, 40, p. 465–471.

16. Follath, F., Cleland, J. G. F., Just, H. et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double blind study. Lancet, 2002, 360, p. 196–202.

17. Moiseyev, V. S., Poder, P., Andrejevs, N. et al. Safety and efficacy of a novel calcium sensitiser, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomised, placebo-controlled, double blind study (RUSSLAN). Eur. Heart J., 2002, 23, p. 132–142.

18. Zairis, M. N., Apostolatos, C., Anastassiadis, F. et al. Comparison of the effect of levosimendan, or dobutamin or placebo in chronic low output decompensated heart failure. Calcium Sensitizer or Inotrope or None in low output heart failure (CASINO) study. Eur. J. Heart Fail., 2004, 3, Suppl. 1, 66, abstract 273.

19. Mebazaa, A., Nieminen, M. S., Packer, M., Cohen-Solal, A., Kleber, F. X., Pocock, S. J., Thakkar, R., Padley, R. J., Põder, P., Kivikko, M., SURVIVE Investigators Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA, 2007, 297, p. 1883–1891.

20. Yamani, M. H., Haji, S. A., Starling, R. C. et al. Comparison of dobutamine-based and milrinone-based therapy for advanced decompensated congestive heart failure: Hemodynamic efficacy, clinical outcome, and economic impact. Am. Heart J., 2001, 142, p. 998–1002.

21. Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST Segment Elevation Acute Coronary Syndrome of the European Society of Cardiology. Eur. Heart J., 2007, 28, p. 1598–1660.

22. Samama, M. M., Cohen, A. T., Darmon, J. Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N. Engl. J. Med., 1999, 341, p. 793–800.

23. deGoma, E. M., Vagelos, R. H., Fowler, M. B. et al. Emerging therapies for the management of decompensated heart failure. J. Am. Coll. Cardiol., 2006, 48, p. 2397–2409.

24. Liesching, T., Kwok, H., Hill, N. S. Acute applications of noninvasive positive pressure ventilation. Chest, 2003, 124, p. 699–713.

25. Peter, J. V., Moran, J. L., Phillips-Hughes, J. et al. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet, 2006, 367, p. 1155–1163.

26. Neuberg, G. W., Miller, A. B., O´Connor, C. M. et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am. Heart J., 2002, 144, p. 31–38.

27. Bellomo, R., Ronco, C. Continuous haemofiltration in the intensive care unit. Crit. Care, 2000, 4, p. 339–345.

28. Costanzo, M. R., Guglin, M. E., Saltzberg, M. T. et al. For the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol., 2007, 49, p. 675–683.

29. Kettner, J. Mechanické podpory krevního oběhu. Cor. Vasa., 2003, 45, 9, p. 437–443.

30. Kettner, J. Mechanické srdeční podpory u závažného srdečního selhání. Postgrad Med. (mimořádná příloha), 2007, 9, p. 44–50.